Edition:
India

Tonix Pharmaceuticals Holding Corp (TNXP.OQ)

TNXP.OQ on NASDAQ Stock Exchange Global Market

4.10USD
2:29am IST
Change (% chg)

$0.40 (+10.81%)
Prev Close
$3.70
Open
$3.66
Day's High
$4.13
Day's Low
$3.66
Volume
17,888
Avg. Vol
18,035
52-wk High
$9.38
52-wk Low
$2.85

Select another date:

Tue, Nov 7 2017

BRIEF-Tonix Pharmaceuticals Q3 loss per share $0.77

* Tonix Pharmaceuticals reports third quarter 2017 financial results and provides programs update

BRIEF-Tonix Pharma reports outcomes from CMC guidance meeting with FDA on Tonmya

* Tonix Pharmaceuticals reports outcomes from U.S. FDA breakthrough therapy CMC guidance meeting of Tonmya® (cyclobenzaprine hci sublingual tablets) for PTSD

BRIEF-Tonix Pharmaceuticals enters into purchase agreement, registration rights agreement with Lincoln Park Capital Fund

* On Sept. 28 co entered into purchase agreement, registration rights agreement with Lincoln Park Capital Fund LLC

BRIEF-Tonix Pharmaceuticals receives European patent for the active ingredient in Tonmya

* Tonix Pharmaceuticals receives European patent for the active ingredient in Tonmya® (cyclobenzaprine hcl sublingual tablets) Source text for Eikon: Further company coverage:

BRIEF-Tonix Pharmaceuticals elects Margaret Smith Bell to the Board of Directors

* Tonix Pharmaceuticals elects Margaret Smith Bell to the Board of Directors Source text for Eikon: Further company coverage:

BRIEF-Tonix Pharmaceuticals presents additional phase 2 clinical results, ongoing phase 3 trial design of Tonmya at 2017 Military Health System Research Symposium

* Tonix Pharmaceuticals presented additional phase 2 clinical results in military-related PTSD and design of ongoing phase 3 trial at the 2017 Military Health System Research Symposium

BRIEF-Tonix Pharmaceuticals to present at Military Health System Research Symposium

* Tonix Pharmaceuticals to present additional phase 2 clinical results and design of ongoing phase 3 trial in military-related ptsd at the 2017 military health system research symposium Source text for Eikon: Further company coverage:

BRIEF-Tonix Pharmaceuticals Holding reports Q2 loss per share $0.65

* Tonix Pharmaceuticals reports second quarter 2017 financial results and provides programs update

BRIEF-Tonix Pharmaceuticals files for a mixed shelf of up to $150 mln

* Tonix Pharmaceuticals Holding Corp files for a mixed shelf of up to $150 million - SEC filing‍​ Source text: (http://bit.ly/2vX1sM0) Further company coverage:

BRIEF-Tonix Pharmaceuticals reports conditional acceptance of Tonmya as proposed brand name for TNX-102 SL

* Tonix Pharmaceuticals Holding Corp- U.S. FDA conditionally accepted proposed trade name Tonmya for tnx-102 sl for management of ptsd

Select another date: